Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

The stock's fall snapped a two-day winning streak.

Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

The projected fair value for Abbott Laboratories is US$132 based on 2 Stage Free Cash Flow to Equity With US$116 share price, Abbott Laboratories appears to be trading close to its estimated fair ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. As of August 26, 2024, the average one-year price ...